Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
Antimicrobial prescribing (23)
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (1904)
NICE advice (320)
Quality standard (198)
Guidance programme
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (225)
COVID-19 rapid guidelines (3)
Diagnostics guidance (50)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (603)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (341)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (797)
Apply filters
Showing 1 to 25 of 1904
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
TA1017
20 November 2024
20 November 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
TA1018
20 November 2024
20 November 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
TA1019
20 November 2024
20 November 2024
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction
IPG794
14 November 2024
14 November 2024
Elafibranor for previously treated primary biliary cholangitis
TA1016
14 November 2024
14 November 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
TA1014
13 November 2024
13 November 2024
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
TA1015
13 November 2024
13 November 2024
Endometriosis: diagnosis and management
NG73
6 September 2017
11 November 2024
Menopause: identification and management
NG23
12 November 2015
7 November 2024
Avapritinib for treating advanced systemic mastocytosis
TA1012
6 November 2024
6 November 2024
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices
DG61
24 October 2024
24 October 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
TA1010
23 October 2024
23 October 2024
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
TA1013
23 October 2024
23 October 2024
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD)
DG60
21 October 2024
21 October 2024
Belzutifan for treating tumours associated with von Hippel-Lindau disease
TA1011
16 October 2024
16 October 2024
Acute kidney injury: prevention, detection and management
NG148
18 December 2019
16 October 2024
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
TA1009
2 October 2024
2 October 2024
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
TA1008
25 September 2024
25 September 2024
Burosumab for treating X-linked hypophosphataemia in children and young people
HST8
10 October 2018
20 September 2024
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
TA1007
17 September 2024
17 September 2024
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)
TA1006
12 September 2024
12 September 2024
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
TA1002
11 September 2024
11 September 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
TA1003
11 September 2024
11 September 2024
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
TA1004
11 September 2024
11 September 2024
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA1005
11 September 2024
11 September 2024
Current page
1
2
3
…
77
Page
1
of
77
Next page
Results per page
10
25
50
All
Back to top